Chad Bousman

Review and Consensus on Pharmacogenomic Testing in Psychiatry

Chad A Bousman, Susanne A Bengesser, Katherine J Aitchison, Azmeraw T Amare, Harald Aschauer, Bernhard T Baune, Bahareh Behroozi Asl, Jeffrey R Bishop, Margit Burmeister, Boris Chaumette, Li-Shiun Chen, Zachary A Cordner, Juergen Deckert, Franziska Degenhardt, Lynn E DeLisi, Lasse Folkersen, James L Kennedy, Teri E Klein, Joseph L McClay, Francis J McMahon, et al.

Journal article  |  2020  |  Pharmacopsychiatry

The implementation of pharmacogenomic (PGx) testing in psychiatry remains modest, in part due to divergent perceptions of the qual..

Individual deviations from normative models of brain structure in a large cross-sectional schizophrenia cohort

Jinglei Lv, Maria Di Biase, Robin FH Cash, Luca Cocchi, Vanessa L Cropley, Paul Klauser, Ye Tian, Johanna Bayer, Lianne Schmaal, Suheyla Cetin-Karayumak, Yogesh Rathi, Ofer Pasternak, Chad Bousman, Christos Pantelis, Fernando Calamante, Andrew Zalesky

Journal article  |  2020  |  Molecular Psychiatry

The heterogeneity of schizophrenia has defied efforts to derive reproducible and definitive anatomical maps of structural brain ch..

EPA and DHA as markers of nutraceutical treatment response in major depressive disorder

Kiki P van der Burg, Lachlan Cribb, Joseph Firth, Diana Karmacoska, David Mischoulon, Gerard J Byrne, Chad Bousman, Con Stough, Jenifer Murphy, Georgina Oliver, Michael Berk, Chee H Ng, Jerome Sarris

Journal article  |  2020  |  European Journal of Nutrition

PURPOSE: Depression clinical trials are increasingly studying biomarkers to predict and monitor response to treatment. Assessment ..

Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients

Chaten D Jessel, Sam Mostafa, Maria Potiriadis, Ian P Everall, Jane M Gunn, Chad A Bousman

Journal article  |  2020  |  Pharmacogenetics and Genomics

OBJECTIVE: To describe the usage patterns of antidepressants with published CYP2D6- and CYP2C19-based prescribing guidelines among..

Thoughtful Clinical Use of Pharmacogenetics in Child and Adolescent Psychopharmacology.

Laura B Ramsey, Lisa B Namerow, Jeffrey R Bishop, J Kevin Hicks, Chad Bousman, Paul E Croarkin, Carol A Mathews, Sara L Van Driest, Jeffrey R Strawn

Journal article  |  2020  |  Journal of the American Academy of Child & Adolescent Psychiatry

AACAP's recent policy statement on Clinical Use of Pharmacogenetic Tests in Prescribing Psychotropic Medications for Children and ..

Reporting of clozapine-induced gastrointestinal hypomotility and factors associated with fatal outcomes in Canada: A pharmacovigilance database study.

Cecilia L Liu, Abdullah Al Maruf, Chad A Bousman

Journal article  |  2020  |  Psychiatry Research

Clozapine-induced gastrointestinal hypomotility (CIGH) is poorly understood and potentially life-threatening. Herein, we present t..

Cognitive reserve attenuates age-related cognitive decline in the context of putatively accelerated brain ageing in schizophrenia-spectrum disorders

Tamsyn E Van Rheenen, Vanessa Cropley, Birgitte Fagerlund, Cassandra Wannan, Jason Bruggemann, Rhoshel K Lenroot, Suresh Sundram, Cynthia Shannon Weickert, Thomas W Weickert, Andrew Zalesky, Chad A Bousman, Christos Pantelis

Journal article  |  2020  |  Psychological Medicine

BACKGROUND: In schizophrenia, relative stability in the magnitude of cognitive deficits across age and illness duration is inconsi..

Commercial Pharmacogenetic Tests in Psychiatry: Do they Facilitate the Implementation of Pharmacogenetic Dosing Guidelines?

Mikayla Fan, Chad A Bousman

Journal article  |  2020  |  Pharmacopsychiatry

INTRODUCTION: Expert groups have created dosing guidelines to facilitate the implementation of pharmacogenetic knowledge into clin..

The ubiquitin proteasome system and schizophrenia

Sandra Luza, Carlos M Opazo, Chad A Bousman, Christos Pantelis, Ashley I Bush, Ian P Everall

Journal article  |  2020  |  The Lancet Psychiatry

The ubiquitin-proteasome system is a master regulator of neural development and the maintenance of brain structure and function. I..

Pharmacogenetic Implications for Antidepressant Pharmacotherapy in Late-Life Depression: A Systematic Review of the Literature for Response, Pharmacokinetics and Adverse Drug Reactions

Victoria S Marshe, Farhana Islam, Malgorzata Maciukiewicz, Chad Bousman, Harris A Eyre, Helen Lavretsky, Benoit H Mulsant, Charles F Reynolds, Eric J Lenze, Daniel J Mueller

Journal article  |  2020  |  American Journal of Geriatric Psychiatry

Affecting up to 15% of older adults, late-life depression (LLD) is characterized by the occurrence of depressive symptoms after th..